Emma Zattarin

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Francesca Ligorio, Giovanni Fucà, Emma Zattarin et al. · Cancers · 2021 · 107 citations · Full text

Medicine, Immunology, Oncology +17

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

Federico Nichetti, Francesca Ligorio, Emma Zattarin et al. · Cancers · 2019 · 67 citations · Full text

Medicine, Oncology, Pharmacology +15

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Luca Cantini, Giulia Mentrasti, Gian Luigi Russo et al. · ESMO Open · 2022 · 65 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Francesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli et al. · Cancer Letters · 2021 · 44 citations

Medicine, Cancer Biology, Oncology +16

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy

Arsela Prelaj, Mattia Boeri, Alessandro Robuschi et al. · Cancers · 2022 · 31 citations · Full text

Medicine, Biomedical Informatics, Oncology +17